RxDoctor Payments Data

Maridez Jenkins

Family · Walnut Creek, CANPI 1245570266

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.3% of the total across 318 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by AbbVie at 40.6% of the total. 2025 is the largest year on record at $2,973, 8.7 times the $340 reported in 2021. Among family clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,563in general payments, 2019–2025

Across 318 payments — averaging $20.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Neurocrine Biosciences, Inc.$1K
  • Teva Pharmaceuticals USA, Inc.$650
  • Pfizer$566
  • Amneal Pharmaceuticals LLC$366
  • UCB, Inc.$252
  • plus $897 from 14 others

What the payments were for

  • Food & beverage$6,45198%
  • Education$1112%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,563 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.

See all family providers in California →

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant25$30,063
Aimovig AutoinjectorErenumab-Aooe32$28,874
Nurtec OdtRimegepant Sulfate13$19,213
Emgality PenGalcanezumab-Gnlm19$13,031
Memantine Hcl103$2,126
Donepezil Hcl150$1,376
RizatriptanRizatriptan Benzoate38$630
Propranolol Hcl32$499
Gabapentin72$489
Sumatriptan Succinate32$405
Nortriptyline Hcl34$398
Venlafaxine Hcl ErVenlafaxine Hcl21$189
Duloxetine Hcl16$143
Metoprolol Succinate11$111
Quetiapine Fumarate17$80

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy$2,667$30,06325 claims
PfizerNurtec Odt$566$19,21313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.

Other family in Walnut Creek

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →